Vioxx trial data shows early heart risk
Vioxx trial data shows early cardiovascular risk — Provides lessons for post-market pharmaceutical safety. – US researchers revealed that the heart complications after taking Vioxx, the nonsteroidal anti-inflammatory drug (rofecoxib), could have been identified nearly four years before its manufacturer Merck pulled the drug from the market.